Catalent Pharma Solutions, the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products, today announced it has appointed Steven Fasman
as Senior Vice President and General Counsel, effective immediately.
John Chiminski, President and CEO, Catalent Pharma Solutions said, “I
am delighted that Steven Fasman has joined Catalent. He is widely
respected as a talented lawyer with a proven record of leadership in
results-focused environments, making him the ideal person for this
important position on Catalent’s executive leadership team.”
Steven Fasman joins Catalent with an accomplished legal career and
extensive experience in a broad range of industries in both private
practice and corporate in-house roles. Most recently he served as
Executive Vice President of Law at MacAndrews & Forbes Holdings, Inc., a
private investment firm with interests in bio-technology, consumer
products, banking, media, e-commerce, and other businesses. As the
senior lawyer in the MacAndrews & Forbes legal department, he oversaw
all legal aspects pertaining to its business transactions, including
mergers and acquisitions, intellectual property, SEC filings, regulatory
issues, and commercial deals.
From 2008 to 2011, he concurrently served as the Chief Legal Officer and
Chief Compliance Officer for M&F Worldwide Corp., a diversified,
NYSE-listed company with $1.9 billion in annual revenue.
Mr. Fasman spent his early career at the top-tier, New York City law
firm of Paul, Weiss, Rifkind, Wharton & Garrison, where he focused on
domestic and international litigation and regulatory proceedings.
A law-graduate of Yale University with a bachelor’s degree in math from
Princeton University, Mr. Fasman is currently President and a trustee of
the Jewish Board of Family & Children’s Services in New York City. He is
married with two children.
Notes for editors:
About Catalent
Catalent Pharma Solutions, is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs approximately
8,000 people, including over 1,000 scientists, at nearly 30 facilities
across 5 continents and in fiscal 2014 generated more than $1.8 billion
in annual revenue. Catalent is headquartered in Somerset, N.J. For more
information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
For Catalent Pharma Solutions
Chris Halling, +44 (0)7580 041073
chris.halling@catalent.com
or
Richard Kerns, +44 (0)161 728 5880
richard@nepr.eu